Janux stock plunges after hours following mCRPC trial data
Johnson & Johnson (NYSE:JNJ), a ten percent owner of CVRx, Inc. (NASDAQ:CVRX), sold 6,337 shares of CVRx common stock on November 26, 2025. The sales occurred at prices ranging from $10.00 to $10.23, with an average price of $10.03, totaling approximately $63,560.
Following the transaction, Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson, indirectly holds 4,040,861 shares of CVRx.
In other recent news, CVRx Inc. reported its third-quarter 2025 financial results, revealing revenue of $14.7 million, which represents a 10% increase compared to the previous year. This revenue exceeded analyst estimates from both Cantor Fitzgerald and Canaccord Genuity, as well as the FactSet consensus. Additionally, the company’s earnings per share (EPS) reported a loss of $0.49, which was slightly better than the anticipated loss of $0.50. Following these results, Cantor Fitzgerald raised its price target for CVRx to $13.00, maintaining an Overweight rating on the stock. Canaccord Genuity also increased its price target to $11.00, continuing to hold a Buy rating. Furthermore, the Centers for Medicare & Medicaid Services (CMS) finalized its 2026 payment rule, maintaining CVRx’s Barostim procedure under New Technology APC 1580, ensuring payment stability for the company’s neurostimulation therapy. These developments reflect the company’s ongoing financial performance and strategic positioning in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.